A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)

National Cheng Kung University Hospital-Clinical Trial Center ( Site 3803), Tainan City

Austin Health-Cancer Clinical Trials Centre ( Site 3950), Heidelberg

Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Site 3951), Brisbane

National Taiwan University Hospital-Oncology ( Site 3801), Taipei

Icahn School of Medicine at Mount Sinai ( Site 3018), New York

Memorial Sloan Kettering Cancer Center ( Site 3031), New York

UPMC Hillman Cancer Center ( Site 3014), Pittsburgh

Ospedale San Raffaele-Oncologia Medica ( Site 3403), Milan

Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 3405), Milan

Centre Georges François Leclerc-Centre de recherche clinique ( Site 3608), Dijon

Duke Cancer Institute ( Site 3027), Durham

Hospital Clinico San Carlos ( Site 3765), Madrid

Emory University School of Medicine ( Site 3043), Atlanta

Oncopole Claudius Regaud ( Site 3610), Toulouse

CHU de Bordeaux Hop St ANDRE ( Site 3607), Bordeaux

Cleveland Clinic-Taussig Cancer Center ( Site 3036), Cleveland

Indiana University Melvin and Bren Simon Cancer Center ( Site 3011), Indianapolis

Siteman Cancer Center ( Site 3038), St Louis

centre hospitalier lyon sud ( Site 3606), Pierre-Bénite

Hôpital Européen Georges Pompidou ( Site 3605), Paris

Anschutz Cancer Pavilion ( Site 3017), Aurora

Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 3406), Napoli

Chang Gung Memorial Hospital at Kaohsiung-Oncology and Hematology ( Site 3802), Kaohsiung City

Huntsman Cancer Institute-HCI Clinical Trials Office ( Site 3041), Salt Lake City

University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 3045), Orange

UCSF Medical Center at Mission Bay ( Site 3044), San Francisco

Bradford Hill Norte ( Site 3152), Antofagasta

ONCOCENTRO APYS-ACEREY ( Site 3158), Viña del Mar

Rambam Health Care Campus-Oncology Division ( Site 3501), Haifa

Rabin Medical Center-Oncology ( Site 3504), Petah Tikva

Sheba Medical Center-ONCOLOGY ( Site 3503), Ramat Gan

FALP-UIDO ( Site 3151), Santiago

Bradfordhill-Clinical Area ( Site 3155), Santiago

Moores Cancer Center ( Site 3028), La Jolla

Dana-Farber Cancer Institute ( Site 3047), Boston

The Ottawa Hospital - General Campus-The Ottawa Hospital Cancer Centre ( Site 3105), Ottawa

Sunnybrook Research Institute - Odette Cancer Centre ( Site 3108), Toronto

Princess Margaret Cancer Centre ( Site 3106), Toronto

Maastricht UMC+ ( Site 3304), Maastricht

Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL)-medical oncology ( Site 3302), Amsterdam

Erasmus Medisch Centrum-Medical Oncology ( Site 3303), Rotterdam

Severance Hospital, Yonsei University Health System-Medical oncology ( Site 3903), Seoul

Asan Medical Center-Department of Oncology ( Site 3901), Seoul

Samsung Medical Center ( Site 3902), Seoul

Hospital Universitari Vall d'Hebron ( Site 3767), Barcelona

St Bartholomew's Hospital-Centre for Experimental Cancer Medicine ( Site 3206), London

ROYAL MARSDEN HOSPITAL (CHELSEA) ( Site 3201), London